Bacteriophage

iNtRON, Development of PHAGERIA® Anti-Cancer Candidate with Enhanced Antimicrobial Activity by Robot Bacteriophage platform technology

Retrieved on: 
Thursday, February 15, 2024
Biotechnology, CRISPR, Intron, Robot, Bacteriophage, Gene, Plasma protein binding, Mutation, Colorectal cancer, Research, SON

BOSTON, Feb. 14, 2024 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com) has announced today that New Drug Part has secured a potent anti-cancer candidate, PHAGERIA®, with broad antimicrobial activity against ETBF (Enterotoxigenic B. fragilis), a harmful microbe associated with colorectal cancer.

Key Points: 
  • iNtRON stated that following the proprietary development of the Robot Bacteriophage 2nd generation technology, additional in-vitro evolution technology was applied.
  • The Company previously secured the technology to customize and edit bacteriophage genomes as desired using tailored CRISPR/Cas technology and Random Transposon Mutagenesis in 2022.
  • Recently, the Company has advanced this technology further to develop a more potent anti-cancer candidate, PHAGERIA®.
  • This achievement is significant as it is the first instance of applying in-vitro Evolution technology to ETBF bacteriophages, demonstrating the excellence of the bacteriophage gene editing technology (CRISPR/Cas) and Robotic Bacteriophage improvement platform technology of the Company.

PhageLab Raises $11 Million to Develop Bacteriophage Solutions to Treat Bacterial Outbreaks in the Livestock Industry

Retrieved on: 
Tuesday, January 23, 2024
Data Management, Other Science, Technology, FDA, Research, Other Health, Pharmaceutical, Infectious Diseases, Genetics, Fitness & Nutrition, Clinical Trials, Nanotechnology, Artificial Intelligence, Biotechnology, Software, Health, Hardware, Science, Agriculture, Veterinary, Natural Resources, Bacteriophage, Livestock, Policy, Multimedia, Gastroenteritis, Collaborative Fund, Data, IPPE

PhageLab will also use the funding to expand its global team, which currently has close to 100 employees across Latin America and Europe.

Key Points: 
  • PhageLab will also use the funding to expand its global team, which currently has close to 100 employees across Latin America and Europe.
  • Antibiotic-resistant outbreaks in livestock farming have been increasing, due to the high emergence rate of multidrug treatment-resistant bacteria.
  • The platform employs AI to generate “customized cocktails,” that can effectively manage pathogenic bacteria in the livestock industry and reduce antibiotic dependence.
  • PhageLab uses this library to create custom solutions in 45 days, that is safe and effective for use to eliminate livestock bacteria.

Wistar Scientists Identify Esophageal Cancer Biomarkers

Retrieved on: 
Wednesday, December 6, 2023
RNA, Wistar Institute, Ferroptosis, Collaborative writing, RNA-Seq, National Cancer Institute, Biomedical Research, Culture, Mechanics, Tumor microenvironment, Ellen, Virus, ESCA, Messenger, Prognosis, Health, Ageing, Incidence, Neoplasm, Cancer, International Society, University, University of Pennsylvania, Ecology, Gene expression, Gene, Biomarker, Machine learning, Cell, Patient, Qi, Iron, NCI, Bacteriophage, Esophageal cancer, Carnegie Mellon University

Philadelphia, PA, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Wistar scientists have developed a new tool that can help identify cancer-associated microbes by using machine learning technology.

Key Points: 
  • Philadelphia, PA, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Wistar scientists have developed a new tool that can help identify cancer-associated microbes by using machine learning technology.
  • Under the leadership of Dr. Noam Auslander — assistant professor in the Ellen and Ronald Caplan Cancer Center’s Molecular & Cellular Oncogenesis Program — the group has analyzed short read RNA-sequencing data to detect biomarkers for esophageal carcinoma, or ESCA.
  • Since 1972, the Institute has held National Cancer Institute (NCI)-designated Cancer Center status.
  • Wistar scientists are dedicated to solving some of the world’s most challenging problems in the field of cancer and immunology, advancing human health through early-stage discovery and training the next generation of biomedical researchers.

TeraPore Launches IsoBlock® VF Viral Filtration Product Line with Proprietary Membrane Technology that Delivers Consistent Results

Retrieved on: 
Wednesday, December 6, 2023
Science, Other Science, Biotechnology, Pharmaceutical, Other Manufacturing, Health, Chemicals, Plastics, Manufacturing, Bacteriophage, Research, Parvoviridae, Membrane, Polymer, Patient, Intelligence, Semiconductor, Biomanufacturing, VF, Filtration, Vaccine, Fine chemical

TeraPore Technologies , an innovator in nanofiltration membranes, has commercially launched the flagship IsoBlock® VF product line for parvovirus removal from biopharmaceuticals.

Key Points: 
  • TeraPore Technologies , an innovator in nanofiltration membranes, has commercially launched the flagship IsoBlock® VF product line for parvovirus removal from biopharmaceuticals.
  • During evaluations at multiple customer sites across different novel antibody constructs, IsoBlock VF has demonstrated robust and consistent performance.
  • The surface chemistry and membrane structure of IsoBlock VF were developed to minimize fouling for stable, predictable VF performance.
  • TeraPore’s VF product provides biomanufacturers with a solution that is adaptable in traditional stainless-steel facilities or the newer single-use operations.

Basilea announces exclusive license and option agreement for potential first-in-class clinical-stage antibacterial agent

Retrieved on: 
Tuesday, October 31, 2023
KOSDAQ, Trial of the century, South Korea, MSSA, Bacteriophage, Biofilm, Intron, Gram-positive bacteria, Infection, Virus, Exercise, Biotechnology, A-DNA, Antimalarial medication, MRSA, LR, Bacteria, Korea, Patient, Death, Pharmaceutical industry, Vaccine, Basel, Allschwil

Tonabacase is a potential first-in-class clinical-stage antibacterial of the endolysin class.

Key Points: 
  • Tonabacase is a potential first-in-class clinical-stage antibacterial of the endolysin class.
  • Over the course of 2024, Basilea will investigate various hypotheses in a number of preclinical studies to determine the optimal future clinical development program for tonabacase.
  • Upon successful completion of the preclinical evaluation phase, Basilea will have the exclusive option to license tonabacase for further clinical development and commercialization.
  • This transaction has no impact on Basilea’s financial guidance for 2023, provided on August 15, 2023.

Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023

Retrieved on: 
Thursday, October 19, 2023
Infection, NYSE, MS, Bacteriophage, Pharmaceutical industry

LOS ANGELES, Oct. 19, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical stage biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that its Chief Medical Officer, Mina Pastagia, M.D., MS, will deliver a presentation at Phage Futures: Global Digital Summit 2023, which is being held virtually on October 25th.

Key Points: 
  • LOS ANGELES, Oct. 19, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical stage biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that its Chief Medical Officer, Mina Pastagia, M.D., MS, will deliver a presentation at Phage Futures: Global Digital Summit 2023, which is being held virtually on October 25th.

Nine New Products Announced at dōTERRA Global Convention

Retrieved on: 
Thursday, September 14, 2023
Serenity, PB, Paraben, Education, Nature, Bacteriophage, Lavandula, Sleep, Skin, Nutrient, Respiratory system, Research, Absorption, Sensation, Sale, Massage, Science, Calcium, Somatosensory system, Lemon, Immune system, Cypress, Relaxation, Environment, Phosphorus, Abies sibirica, Hagens Berman–Supermint, Family, Probiotic, Cryptocurrency, Perfume, Dietary supplement, Birch

PLEASANT GROVE, Utah, Sept. 14, 2023 /PRNewswire/ -- dōTERRA announced the launch of several new essential oils and essential oil blends at their global convention today as well as additions to their sleep and gut health systems. dōTERRA remains firm in their goal to provide high quality products and sustainably sourced essential oils.

Key Points: 
  • dōTERRA remains firm in their goal to provide high quality products and sustainably sourced essential oils.
  • With dōTERRA taking a sustainable approach to bring pure Birch to life, SEAL Awards recognized dōTERRA as a winner of the Environmental Initiative Award.
  • "2023 marks 15 years of dōTERRA, which means we have some very special products lined up for this year's convention," said Mike Mangelson, senior director business development.
  • "Our global convention is a time to gain education and experience with our new products.

CerroZone™ Meets and Exceeds Requirements of ASHRAE Standard 241-2023, Control of Infectious Aerosols

Retrieved on: 
Tuesday, September 5, 2023
Other Manufacturing, Hardware, General Health, Health, Medical Devices, Infectious Diseases, Technology, Manufacturing, Berkshire Hathaway, ASHRAE, Atmosphere, Bacteriophage, Robinson, Hecto-, Original equipment manufacturer, Marmon, COVID-19, Refrigeration, Architecture, Micrometre, Marmon Group, Research, Standard, UL, ISS National Lab, Ventilation, Pennsylvania State University, School, Intertek, Publication, Lawrence Berkeley National Laboratory, Particulates, Certification, Bacteria, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Virus, Food, Safety, Heating, ventilation, and air conditioning

FDA approval was contingent on extensive testing at accredited independent third-party facilities.

Key Points: 
  • FDA approval was contingent on extensive testing at accredited independent third-party facilities.
  • CerroZone’s mobile, mini, and in-ceiling/wall mount units are designed to purify air in buildings such as schools, retail environments, offices, and other indoor spaces.
  • Intertek considers emissions of 0.005 ppm or less to be negligible per UL 2998, the North American industry standard for ozone testing.
  • The CerroZone unit recorded at only 0.001 ppm, five times lower than the UL 2998 standard.

Spectra 1000 Redefines Infection Control: Groundbreaking Disinfection System Demonstrates >99.98% Effectiveness Against Candida auris

Retrieved on: 
Tuesday, July 11, 2023
Aureus, Infection, Atmosphere, Medline Industries, SARS-CoV-2, Cladosporium, Bacteriophage, Internet of things, Candida auris, Patient, Patient safety, Disinfectant, Escherichia coli, Immunodeficiency, Fungal infection, Auris, Staphylococcus aureus, Pharmaceutical industry, Vaccine

CHESTER, Conn., July 11, 2023 /PRNewswire/ -- Presenting the Spectra 1000, a pioneering disinfection system that has demonstrated exceptional effectiveness against Candida auris, a yeast pathogen causing global concern in the healthcare community.

Key Points: 
  • CHESTER, Conn., July 11, 2023 /PRNewswire/ -- Presenting the Spectra 1000, a pioneering disinfection system that has demonstrated exceptional effectiveness against Candida auris, a yeast pathogen causing global concern in the healthcare community.
  • The Spectra 1000 isn't just a new product; it redefines the paradigm of infection control.
  • Its exceptional blend of rapid room treatment times and unparalleled effectiveness is unrivaled in the industry.
  • In a world where infection control has become a top priority, the Spectra 1000 emerges as an exceptional solution for numerous facilities.

Bacterial Therapeutics Market Analysis Report 2023 - Recent Developments and the Need for Antibiotic Innovation - ResearchAndMarkets.com

Retrieved on: 
Monday, July 10, 2023
Biotechnology, Health, Other Health, Bacteriophage, Antibiotic, Bacteria, Probiotic, Synthetic, Antibody, Vaccine

The "Bacterial Therapeutics Beyond Antibiotics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Bacterial Therapeutics Beyond Antibiotics" report has been added to ResearchAndMarkets.com's offering.
  • As bacteria grow resistant to conventional antibiotics, alternatives are being investigated, including antibodies, probiotics, bacteriophages, and antimicrobial peptides currently undergoing clinical trials.
  • The specificity of antibodies, and the inability of bacteria to develop resistance against them, make antibodies attractive, albeit expensive, alternative therapeutic agents.
  • Synthetic peptides and synthetic Antibiotic membrane-active agents might herald a shift in treatment options.